Evidence map›Paper›PMID 27749016›Full record

ArticleProteomics2016

Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry.

Xingwang Jia, Jing Chen, Shisheng Sun, Weiming Yang, Shuang Yang, Punit Shah, Naseruddin Hoti, Bob Veltri, Hui Zhang

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Mass Spectrometry-Based Glycoproteomics and Prostate Cancer.International journal of molecular sciences · 2021
    Review
  10. Clinically Viable Assay for Monitoring Uromodulin Glycosylation.Journal of the American Society for Mass Spectrometry · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Glycomics of prostate cancer: updates.Expert review of proteomics · 2019
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xingwang JiaDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Jing ChenDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Shisheng SunDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Weiming YangDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Shuang YangDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Punit ShahDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Naseruddin HotiDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Bob VeltriDepartment of Urology, Johns Hopkins University, Baltimore, MD, USA.
Hui ZhangDepartment of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USChinese PLA General Hospital · CN

Funding

Shared Resource CoresP01HL107153 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2011 to 2017
$16.8M
Proteome Characterization Center: A Genoproteomics Pipeline for Cance ResearchU24CA160036 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2011 to 2016
$10.7M
Glycoprotein biomarkers for the early detection of aggressive prostate cancerU01CA152813 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHANG, HUI · 2010 to 2021
$6.2M
NCI NIH HHS U01 CA152813NCI NIH HHS U24 CA160036NHLBI NIH HHS P01 HL107153
6 · The paper itself

Abstract

Clinical management of prostate cancer remains a significant challenge due to the lack of available tests for guiding treatment decisions. The blood prostate-specific antigen test has facilitated early detection and intervention of prostate cancer. However, blood prostate-specific antigen levels are less effective in distinguishing aggressive from indolent prostate cancers and other benign prostatic diseases. Thus, the development of novel approaches specific for prostate cancer that can differentiate aggressive from indolent disease remains an urgent medical need. In the current study, we evaluated urine specimens from prostate cancer patients using LC-MS/MS, with the aim of identifying effective urinary prostate cancer biomarkers. Glycoproteins from urine samples of prostate cancer patients with different Gleason scores were characterized via solid phase extraction of N-linked glycosite-containing peptides and LC-MS/MS. A total of 2923 unique glycosite-containing peptides were identified. Glycoproteomic comparison on urine and tissues from aggressive and non-aggressive prostate cancers as well as sera from prostate cancer patients revealed that the majority of AG prostate cancer associated glycoproteins were more readily detected in patient's urine than serum samples. Our data collectively indicate that urine provides a potential source for biomarker testing in patients with AG prostate cancer.

Indexed as

Carbohydrate ConformationCase-Control StudiesChromatography, LiquidGlycoproteinsHumansMaleProstatic NeoplasmsProteomicsSolid Phase ExtractionTandem Mass SpectrometryWorkflowGlycoproteinsAggressiveGlycoproteinGlycoproteomicsProstate cancerUrine

Identifiers

PMID27749016
PMCPMC5407186
OpenAlexW2532094199

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.